Fractyl Health Weight-Maintenance Data Holds After GLP-1 Stop

Evercore ISI analyst Michael DiFiore called the results "clean and clinically meaningful" in a note, adding that the magnitude of weight maintenance exceeded expectations. Canaccord Genuity's Whitney Ijem said the data de-risks the program and positions Rejuva as a potential first-in-class option for the GLP-1 maintenance market.

Fractyl ended the quarter with $142 million in cash, enough to fund operations into 2028, the company said. The REMAIN-1 trial continues to enroll the full cohort, with a second interim analysis expected in the first half of 2027.

A key question for investors is whether the FDA will require a cardiovascular outcomes trial before approval, given the class-wide scrutiny on GLP-1-based therapies. Rajagopalan said the agency has not yet signaled such a requirement. Fractyl plans to discuss the data with the FDA in the second half of 2026 to determine the Phase 3 path.

The company's Alpha Score sits at 62 out of 100, a Moderate rating, reflecting the early-stage nature of the pipeline and the binary risk of regulatory decisions ahead.